en · de · es · fr · pt
peptide-index.peptides7501.com › Faq › Background And Mechanism — Hands-On Walkthrough

Background And Mechanism — Hands-On Walkthrough

By Editorial Desk · published 2026-02-14 · last reviewed 2026-04-02 · Faq

SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-04-02. Anything still debated is marked as such rather than presented as settled.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Related pages on this site

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Supporting material

Reaction to the poem has been mixed. Although its authenticity has been doubted from the beginning, some claimed that it was an "insight" of Li Bai who would foresee the war crime of Japan. Some Chinese felt disgraced by the humor, and blamed the author was so childish and shameful to imitate Li Bai in a bad taste apocryphal poem. However, most people simply took it as a joke.

DiCaprio is regarded as one of the finest actors of his generation. In a 2022 readers' poll by Empire, he was voted one of the 50 greatest actors of all time. The magazine praised his willingness to "go to the ends of the earth (often literally) to get under his characters' skin". Colin Covert of The Seattle Times similarly believed DiCaprio "redefines film stardom" through his willingness to take on challenging roles that few of his contemporaries are capable of performing. Since his international stardom with Titanic (1997), he has admitted feeling nervous about starring in big-budget studio films because of their hype and marketing campaigns. As an actor, he views film as a "relevant art form, like a painting or sculpture. A hundred years from now, people will still be watching that movie." He often plays roles based on real-life people and stories told in specific periods. According to Caryn James, DiCaprio is unafraid of working with established directors on unconventional projects; taking such risks has led him to star in failed films like The Beach (2000), but also his successful collaborations with Martin Scorsese. DiCaprio has described his relationship with Scorsese as dreamlike and admires his knowledge of film, crediting the director with having taught him its history and importance. Scorsese has commented on DiCaprio's ability to repeatedly demonstrate emotion on screen. Jesse Hassenger of The A.V.

Tacrolimus and a related drug for eczema (pimecrolimus) were suspected of carrying a cancer risk, though the matter is still a subject of controversy. The FDA issued a health warning in March 2005 for the drug, based on animal models and a small number of patients. Until further human studies yield more conclusive results, the FDA recommends that users be advised of the potential risks. However, current practice by UK dermatologists is not to consider this a significant real concern and they are increasingly recommending the use of these new drugs. A 2023 systematic review and meta-analysis published in The Lancet Child & Adolescent Health concluded with moderate-certainty evidence that the two drugs were not associated with any increased risk of cancer. In November 2024, International Agency for Research on Cancer (IARC) classified hydrochlorothiazide, voriconazole and tacrolimus as group 1 carcinogens.

Sources: en.wikipedia.org

Supporting material

== External links == ImmPort - Gene summaries, ontologies, pathways, protein/protein interactions and more for genes involved in antigen processing and presentation antigen+presentation at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

The cytoskeleton (cyto- meaning 'cell') is used to stabilize and preserve the form of the cells. It is a dynamic structure that maintains cell shape, protects the cell, enables cellular motion using structures such as flagella, cilia and lamellipodia, and transport within cells such as the movement of vesicles and organelles, and plays a role in cellular division. The cytoskeleton is not a skeleton in the sense that it provides the structural system for the body of an animal; rather, it serves a similar function at the cellular level.

=== Physical symptoms === A low body mass index (BMI) for one's age and height (except in cases of atypical anorexia) Rapid, continuous weight loss Dry hair and skin, hair thinning, as well as hair loss Low body temperature (hypothermia) Raynaud Phenomenon Hypotension or orthostatic hypotension Bradycardia or tachycardia Chronic fatigue Insomnia Severe muscle tension, aches and pains Irregular or absent menstrual periods in women Infertility Gastrointestinal disease Halitosis (from vomiting or starvation-induced ketosis) Abdominal distension Russell's Sign; can be a tell-tale sign of self-induced vomiting with scratches on the back of the hand Tooth erosion Lanugo: soft, fine hair growing over the face and body Orange discoloration of the skin, particularly the feet (carotenosis)

On 30 June 1804, Humboldt, Bonpland, and Montufar departed with their scientific specimens aboard the French frigate La Favorite, sailing from the Delaware River and reaching the open sea by 9 July 1804, thus concluding Humboldt’s American expedition.

Sources: en.wikipedia.org

Notes from published material

A half-life often describes the decay of discrete entities, such as radioactive atoms. In that case, it does not work to use the definition that states "half-life is the time required for exactly half of the entities to decay". For example, if there is just one radioactive atom, and its half-life is one second, there will not be "half of an atom" left after one second. Instead, the half-life is defined in terms of probability: "Half-life is the time required for exactly half of the entities to decay on average". In other words, the probability of a radioactive atom decaying within its half-life is 50%. For example, the accompanying image is a simulation of many identical atoms undergoing radioactive decay. Note that after one half-life there are not exactly one-half of the atoms remaining, only approximately, because of the random variation in the process. Nevertheless, when there are many identical atoms decaying (right boxes), the law of large numbers suggests that it is a very good approximation to say that half of the atoms remain after one half-life. Various simple exercises can demonstrate probabilistic decay, for example involving flipping coins or running a statistical computer program.

=== Electrospray ionization mass spectrometry === Electrospray ionization mass spectrometry is a very versatile technique, consisting in a transfer of the formed complexes from the injected solution to the gas phase by a soft ionization process without strongly perturbing the complex stability. In addition, a small amount of the prepared solution needs to be injected to obtain the speciation spectra. Speciation of several metal ions can be investigated in monophasic solutions at increasing ligand concentration in order to explore all potential complexes. Collision Induced Dissociation (CID) analysis can be also performed to assess the kinetic stability of the formed complexes by discovering the main fragmentation pathway of the ligand. Besides, the protonation effect on the complexation mechanism can be observed by performing analysis on monophasic solutions at increasing nitric acid concentration. Corroboration of the major complexes involved into the extraction process is generally found by performing experiments on biphasic solutions upon extraction tests. Despite versatility of this spectroscopic technique that directly provides information by changing the ligand to metal ratios, its qualitative nature due to instrumental set-up and potential changes in solution chemistry could partially affect species distribution and its ion abundance. For these reasons, corroboration for the speciation results needs to be found by other spectroscopic techniques.

In the final years of his reign, Spain suffered a financial recession that led to a political crisis, which also affected Juan Carlos's popularity and was a key factor in his decision to abdicate in 2014.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Network